CD44 is a biomarker associated with human prostate cancer radiation sensitivity (Q39467150)

12 September 2017

CD44 is a biomarker associated with human prostate cancer radiation sensitivity (English)

1 reference

12 September 2017

0 references

1 reference

WeiWei Xiao

1

1 reference

12 September 2017

Peter H Graham

2

1 reference

12 September 2017

Carl A Power

3

1 reference

12 September 2017

Jingli Hao

4

1 reference

12 September 2017

John H Kearsley

5

1 reference

12 September 2017

Yong Li

6

1 reference

12 September 2017

28 September 2011

1 reference

Clinical & Experimental Metastasis

12 September 2017

1 reference

12 September 2017

29

1 reference

12 September 2017

1

1 reference

12 September 2017

1-9

1 reference

https://scigraph.springernature.com/pub.10.1007/s10585-011-9423-7

12 September 2017

0 references

cites work

Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy.

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

What dose of external-beam radiation is high enough for prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

CD44: from adhesion molecules to signalling regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Involvement of CD44, a molecule with a thousand faces, in cancer dissemination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

A histone deacetylase inhibitor, trichostatin A, enhances radiosensitivity by abrogating G2/M arrest in human carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Radiosensitizing effect of natural and recombinant beta-interferons in a human lung carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Impact of genomic methylation on radiation sensitivity of colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Cancer stem cells: back to Darwin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Association of reactive oxygen species levels and radioresistance in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9423-7

DNA damage and cell cycle checkpoints

21 January 2018

1 reference

12 December 2020

Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12

1 reference

12 December 2020

Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate.

1 reference

12 December 2020

CD44 expression predicts local recurrence after radiotherapy in larynx cancer

1 reference

12 December 2020

Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region

1 reference

12 December 2020

Radical radiotherapy for prostate cancer is the 'only way to go'.

1 reference

12 December 2020

Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?

1 reference

12 December 2020

Mean inactivation dose: a useful concept for intercomparison of human cell survival curves

1 reference

12 December 2020

Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents

1 reference

12 December 2020

10.1007/S10585-011-9423-7

Identifiers

DOI

1 reference

12 September 2017

1 reference